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Abstract: Inhibitors against replacement clotting factors occur in approximately 30%–40% of
patients with hemophilia A and 1.5%–3% of patients with hemophilia B. In this group of patients,
bleeding events are best treated with bypassing agents. Recombinant activated factor VII (rFVIIa)
has become the first-line agent in treating surgical and non-surgical bleeding in many centres with
efficacy at standard 90 µg/kg doses approaching 90%. The greater efficacy is associated with early
initiation of treatment, as well as, possibly larger doses of rFVIIa. A higher concentration appears
to be essential in initiating an adequate thrombin burst, which results in a stable clot. Higher dosage
regimens, home therapy and continuous infusion regimens are continuously evolving as we strive
to define optimal dosing strategies in hemophilia patients. rFVIIa has been a remarkably safe agent
for hemophiliacs but with high dosages being advocated and older patients being given such doses
outside a trial setting, thromboembolic events remain a concern.
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Introduction
The development of alloimmune antibodies against factor VIII has been recognized
since the early treatment of hemophilic patients with blood product transfusion many
decades ago (Munro and Jones 1943). Highly effective treatment and prophylaxis of
bleeding episodes with increasingly purified factor VIII containing products over the
years have been negated by development of inhibitors in approximately 30–40% of
patients with severe hemophilia A (Ehrenforth et al 1992; Scharrer et al 1999; Kreuz
et al 2002). Similar inhibitors have been developed, between 1.5–3% of hemophilia B
patients receiving factor IX concentrates (Warrier and Lusher 1998).
To circumvent their devastating effects against replacement factor concentrates,
treatment strategies for bleeding episodes are based upon the premise of either saturating
inhibitors with excess of clotting factors or bypassing the factor requirement altogether
(von Depka 2005). The first strategy can only be attempted in patients with low inhibitor
levels (<5 Bethesda Units). Bleeding episodes in patients with high responding inhibitor
levels pose a considerable challenge to clinicians and requires the use of bypassing
agents such as prothrombin complexes and recombinant activated factor VIIa (rFVIIa,
Novo Seven). Hemostasis is not assured despite the use these agents and responses
vary between individual patients, with overall costs being potentially prohibitive for
many patients (Allen and Aledort 2006).
rFVIIa is the latest among the limited range of currently available bypassing agents.
Successful use of plasma derived FVIIa in hemophilia A patients with inhibitors was
first reported about 2 decades ago (Hedner and Kiesel 1983). Experience with its
recombinant form in hemophiliacs began in the late 1980’s (Hedner et al 1988) and
represented a major advance in the treatment of patients with inhibitors (Hedner 1990).
The US Food and Drug Administration (FDA) approval for use in both hemophilia AVascular Health and Risk Management 2006:2(4) 434
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and B patients with inhibitors, was attained in 1999. In Europe,
the regulatory approvals have been extended to other
indications such as acquired hemophilia, factor VII
deficiency and Glanzmann’s thrombasthenia. The current
understanding of its hemostatic action suggests that
pharmacologic doses of rFVIIa enhance the thrombin-
generating potential of activated platelets and facilitate full
activation of thrombin-activatable fibrinolytic inhibitor
(TAFI) and factor XIII. The sum result of these processes is
the formation of a stable hemostatic plug, which is resistant
to premature lysis (Hedner 2006). rFVIIa has a short half-life
of 2.9 hours and dosing at intervals of 2–3 hours is necessary
to maintain hemostasis (Lindley et al 1994). Significantly
faster clearance has been observed in children compared to
adults (Villar et al 2004).
In the following sections, we will review various aspects
and issues concerning the use of rFVIIa in treating and
prophylaxing against bleeding episodes, among both
hemophilia A and B patients. Medline and EMBASE electronic
databases were comprehensively searched using the following
terms: recombinant FVIIa, recombinant activated factor VII,
NovoSeven, eptacog alfa and haemophilia/hemophilia. Unless
otherwise stated, the studies and reports mentioned include
both hemophilia A and B patients with inhibitors
Efficacy of rFVIIa in non-surgical
and surgical bleeding
Following the first reported treatment success with rFVIIa
(Hedner et al 1988), many case reports and case series were
published, reporting mostly successful control or prevention
of bleeding in hemophiliacs with inhibitors (Levi et al 2005).
Further suggestions of efficacy came from compilation of data
and reports derived from the databases of the Compassionate
Use Program and later, the Emergency Treatment Study (Bech
1996; Rice and Savidge 1996; Arkin et al 1998; Scharrer 1999;
Arkin et al 2000; Ludlam 2002). Under the first program, 260
patients received rFVIIa for more than 1000 bleeding episodes
over 8 years. Doses of 60–90 µg/kg were used with efficacy
reported to be between 80%–87% in serious bleeds and 91%–
94% in surgical bleeding. In the Emergency Treatment Study,
253 acute bleeding episodes in 127 patients were treated with
rFVIIa at
90 µg/kg, repeated 2-hourly until bleeding stopped. An
efficacy rate of 93% was reported. The compassionate use
program and emergency use study were however not subjected
to the rigorous standards and monitoring of a clinical trial;
hence, a potential for biased and unreliable reporting.
There were, however, two randomized, double blind, multi-
center dose-finding trials that assessed control of bleeding in
non-surgical and surgical bleeding respectively. In the non-
surgical trial (Lusher et al 1998), 84 patients were treated
with either 35 µg/kg or 70 µg/kg of rFVIIa given 2–3 hourly,
for joint, muscle and mucocutaneous bleeding. Both doses
were considered to be equally efficacious with excellent or
effective response in 71% of patients. The second randomized
trial (Shapiro et al 1998) compared a dose of 35 µg/kg against
90 µg/kg in the initiation and maintenance therapy for
bleeding during and after surgery. Intra-operative hemostasis
was achieved in 28 of 29 patients. All 14 high dosed patients
and 12 of 15 low-dosed patients had adequate hemostasis
during the first 48 hours. The higher dose was adjudged to be
more effective.
Accumulated evidence over the years has mostly shown
rFVIIa to be effective in the management of bleeding
episodes. Alternative bypassing agents are largely
preparations of prothrombin complexes in activated or non-
activated forms. Evidence of efficacy for these alternatives
is best described for FEIBA (factor eight bypassing activity),
an activated prothrombin complex. In a double blind
comparison with a non-activated prothrombin complex,
effective non-surgical hemostasis was achieved in 64% vs
52% of hemophilia A patients, in favor of FEIBA (Sjamsoedin
et al 1981). More recent reports suggest an efficacy rate closer
to 80% in both surgical and non-surgical bleeding (Negrier
et al 1997; Hilgartner et al 1990). A randomized multi-center
equivalence study comparing the efficacy of rFVIIa against
FEIBA (FENOC) has also recently been published in abstract
form (Berntorp et al 2005). Sixty-six hemophilia A patients
were randomized to either one dose of FEIBA or two doses of
rFVIIa for bleeding episodes. At 6 hours, 76.1% of FEIBA
treated patients reported cessation of bleeding, in comparison
to 65.2% receiving rFVIIa (confidence intervals for
equivalence –2.7%, 24.5%). Equivalence could not be
concluded for response at 6 hours though they were
determined to be of similar efficacy at 24 and 48 hours.
Despite these inconsistencies, it appears that the two products
may have similar efficacy.
Optimal dosing strategy
Early experience and dose finding trials of rFVIIa have
suggested that a dose of 90–120 µg/kg confers adequate
hemostatic effect for most surgical and non-surgical bleeding.
The initial dose should be high enough to maintain a plasma
level of FVII-coagulant activity (FVII:C) of >6 U/mL forVascular Health and Risk Management 2006:2(4) 435
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several hours (Hedner 1996). Dosing intervals of 2 hours are
recommended, until hemostasis is achieved, irrespective of
bleeding etiology or location. Higher doses of rFVIIa which,
supposedly, ensure the generation of a full thrombin burst,
have been touted to be more efficacious (Cooper et al 2001). A
full thrombin burst is necessary for the formation of a stable
hemostatic plug with a tight fibrin structure, and decrease
susceptibility to fibrinolysis (Blomback et al 1994). Besides
plasma concentration, early administration of rFVIIa is also
important for effective control of bleeding (Lusher 2000).
Strategies targeting these two areas have been studied to
optimize treatment.
Megadose rFVIIa
Incremental doses of rFVIIa have been investigated by various
workers to determine if such a strategy leads to better control
of bleeding without a significant increase in cost (Table 1).
Kenet and colleagues compared an augmented versus a
standard protocol of rFVIIa administration in a small study
population. Initial bolus doses were doubled from 90 µg/kg
to 180 µg/kg with an increase in infusion rates from 15 µg/
kg/h to 30 µg/kg/h and a reduction in total infusion duration
from 12 to 6 hours (Kenet et al 2000). Shorter response time
and duration of therapy was demonstrated in the augmented
protocol. These two protocols were subsequently compared
Table 1 Efficacy of rFVIIa at different bolus dose regimens for the treatment of acute non-surgical bleeding in hemophilia A and B
patients with inhibitors
Study Type of bleeding Number of episodes Dose (µ µ µ µ µg/kg) Number of doses Effective
(no. of patients, used per bleed response (%)
where available)
Lusher et al Joint/muscle/ Joint–59  35 Joint–2.7 71
1998
RCT mucocutaneous Muscle–15 Muscle–3.5 53
Lusher et al Joint/muscle/ Joint–85 70 Joint–3.1 71
1998RCT mucocutaneous Muscle–14 Muscle–3.6 72
Bech 1996
a Joints/muscle 494(111) 60–120 11–65 Joints–79
Muscle–65
Rice and Central nervous 29 (21) 80–100 2–332 84
Savidge system (CNS)
1996
a
Arkin et al Intracranial 13 (12) 90 96.9 83
1998a
Scharrer Joints and other sites 45(23) 90 46.8 69
1999a
Kenet et al Joints and others 114 (3) 300 1 83b
2003
Parameswaran Joint/muscle/ 146 <100 4.3 85
et al 2005 mucocutaneous 154 100–150 5.2 84
136 150–200 3.4 84
119 >200 2.3 97
Santagostino Joints 36(18) 270 1 64
b
et al 2006RCT
Kavakli et al Joints 20(20) 270 1 65
b
2006
RCT
a Studies include non-hemophilic patients and were part of the Compassionate Use Program and Emergency Use Study.
b Results of efficacy was analyzed after single dose of rFVIIa (as allowed by protocols).
Abbreviations: RCT, randomized controlled trials.Vascular Health and Risk Management 2006:2(4) 436
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with a megadose protocol using a single dose of 300 µg/kg
(Kenet et al 2003). Pain relief and response was fastest with
the megadose protocol and most preferred by patients.
However, it consumed more rFVIIa per bleed than the standard
protocol, but less than the augmented protocol. No serious
safety issues were observed. The greater efficacy of high dose
rFVIIa was also suggested by a retrospective analysis of data
from the Haemophilia and Thrombophilia Research Society
Registry (Parameswaran et al 2005). Bleeding episodes were
grouped according to the bolus rFVIIa dose used (Table 1).
The highest efficacy was achieved in the group given >200
µg/kg (97%, compared with 84% in the 3 lower dose groups, p
< 0.001). Doses as high as 346 µg/kg were used without
apparent safety issues.
Two multi-center prospective randomized trials have
compared the use of high dose rFVIIa against standard doses
for home treatment of hemarthroses. The first study was open-
labeled and compared a standard dose of 90 µg/kg (repeated
every 3 hourly if necessary) against a single dose of 270 µg/
kg in a total of 68 bleeding episodes (Santagostino et al
2006). Success rates were identical at all time points (66%
for standard dose vs 64% for high dose at 48 hours) as was
the total dose of rFVIIa used. The second study was double
blinded and used either 3 single doses of 90 µg/kg or a dose
of 270 µg/kg with two placebo doses, given at 3-hour intervals
(Kavakli et al 2006). No significant difference in efficacy
was found (65% for high dose versus 70% for standard dose).
Both studies did not identify significant safety issues with
the high dose regimen. The authors of both papers surmised that
high dose treatment may be preferred by patients because of
the convenience of single administration, without a significant
increase in consumption of rFVIIa. The data on megadosing
are, however, immature and need to be further investigated.
Home treatment
Early treatment of bleeding episodes in hemophiliacs is
generally accorded with a greater rate of success and a reduction
in damage cause by the bleeding. Analysis of experiences
from the compassionate use program, dose finding trials as
well as the US home treatment study, showed that the highest
rate of efficacy and lowest dose requirement of rFVIIa was
found in the home treatment group (Lusher 1998). An efficacy
rate of 92% with a mean of 2.3 doses was achieved, which
was superior to rates achieved when late treatment was given.
The interval between the onset of bleeding and administration
of rFVIIa appears crucial and various trials have studied early
treatment with rFVIIa at home (Ingerslev et al 1998; Key et al
1998; Laurian et al 1998; Santagostino et al 1999; Santagostino
et al 2006; Kavakli et al 2006).
Four studies have investigated home treatment with rFVIIA
at a standard dose of 90 µg/kg given repeatedly every 2–4
hours, if necessary, for up to 12 hours (Ingerslev et al 1998;
Key et al 1998; Laurian et al 1998; Santagostino et al 1999).
Treatment was safe and effective in 79%–93% of bleeding
episodes. Santagostino et al demonstrated that the risk for
partially effective or ineffective response was smaller for
treatment started within 6 hours of the onset of bleeding than
for those started later (OR 0.24, 95% CI, 0.09–0.63)
(Santagostino et al 1999). Early treatment was also
significantly associated with lower rFVIIa usage (median 1.5
doses vs 3, p = 0.07). A significant improvement in response
rate and reduction in doses used was associated with early
treatment in all the 4 studies.
Continuous infusion
Continuous infusion (CI) regimens theoretically offer the
advantage of avoiding the repeated bolus dosing needed to
maintain adequate plasma FVII: C concentrations, with a
potential for reduction in overall rFVIIa requirement. Surgical
patients could derive most benefit because rFVIIa needs to
be given for a few days after surgery. Since the first feasibility
study by Schulman and colleagues (1996), there have been
various studies on CI of rFVIIa at different infusion rates for
surgical procedures and bleeding episodes (Mauser-
Bunschoten et al 1998; Montoro et al 1998; Kenet et al
2000; Smith et al 2001; Mauser-Bunschoten et al 2002;
Ludlam et al 2003). Several studies use an initial bolus dose
of 90–120 µg/kg followed by CI at a rate of 16.5–18 µg/kg/
h, with subsequent adjustments aiming to achieve a FVII:
C level of  >10 U/ml (Mauser-Bunschoten et al 1998; Montoro
et al 1998; Kenet et al 2000; Mauser-Bunschoten et al 2002).
Results have however been inconsistent. Higher infusion rates
and augmented regimens to achieve a higher FVII: C level
have therefore been investigated. Kenet et al (2000) used an
initial dose of 180 µg/kg followed by an infusion of 30 µg/
kg/h. This was 100% effective in securing hemostasis for
surgical intervention and 72% effective for non-surgical
bleeding. Ludlam et al (2003) reported on a regimen using
90 µg/kg as an initial dose, followed by 50 µg/kg/h for major
orthopedic surgery. This achieved a FVII: C of 30 U/mL and
appears to provide good hemostatic control. Such augmented
dosing may however use substantially more rFVII than
conventional CI, standard repeated boluses or even
megadosing (Kenet et al 2003).Vascular Health and Risk Management 2006:2(4) 437
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Despite theoretical advantages, the place of CI therapy
and its optimal delivery and cost-effectiveness remains
controversial. CI may be considered for surgery, complicated
bleeding or delayed treatment, where prolonged therapy may
be required (Abshire and Kenet 2004). The current concept
which places importance on an adequate thrombin burst to
achieve effective hemostasis, will further cloud this picture,
as this phenomenon is better achieved with the high plasma
concentration of rFVIIa that follows the administration of
large bolus doses.
Specific approaches in surgery
RFVIIa has allowed thousands of inhibitor patients to
undergo otherwise high risk elective and emergency
surgeries successfully. Both bolus (Ingerslev et al 1996;
Lusher et al 1998; Shapiro et al 1998; Hvid and Rodriguez-
Merchan 2002) and CI regimens (Schulman et al 1996;
Mauser-Bunschoten et al 1998; Montoro et al 1998; Kenet
et al 2000; Smith et al 2001; Mauser-Bunschoten et al 2002;
Ludlam et al 2003) have been studied in patients
undergoing surgery. Lusher et al (1998) analyzed data on
103 surgical procedures with most patients given an initial
dose of 90 µg/kg (range 60–120 µg/kg). Responses were
rated as excellent in 81% of major surgical procedures, 86%
of and minor procedures and 92% of dental procedures. In
a study by Shapiro et al (1998), bolus doses of 90 µg/kg were
repeated every 2 hours for 48 hours, followed by 2- to 6-
hour intervals for the next 3 days, and all patients had
satisfactory control of bleeding at 48 hours. This regimen
was superior to the comparative regimen of 35 µg/kg and is
the most commonly used bolus regimen dose. A recent
consensus meeting on inhibitor management strategies in
surgeries made the following recommendations (Rodriguez-
Merchan et al 2004). For minor procedures, a bolus dose of
90–120 µg/kg given 2 hourly for up to 4 doses, followed by
3- to 6-hour redosing for 24 hours is recommended. For major
surgeries, a starting dose of 120 µg/kg (150 µg/kg for
pediatrics), followed by 90–120 µg/kg 2 hourly for the first
day, is recommended. Subsequent dosing intervals are 3
hourly for day 2, 4 hourly for days 3–5, and 6 hourly
thereafter as necessary.
Rates for continuous infusion are less well defined with
limited evidence for more specific recommendations. The
same consensus meeting recommended infusion rates ranging
from 15–50 µg/kg/h for up to 14 days. There has also been no
direct comparison between bolus dosing regimens against
continuous infusion protocols.
Safety issues in hemophiliacs
Thrombotic concerns are understandable with a pro-
hemostatic agent such as rFVIIa and thrombogenic
potentials of alternative agents such as FEIBA and other
prothrombin complexes have been well described (Kohler
1999, Ehrlich et al 2002). Thrombotic events related to the
use of rFVIIa in hemophiliacs and other bleeding conditions
have however been low since its first introduction. This is
largely attributed to its action on activated platelets at sites
of bleeding only, and not systemically. Abshire and Kenet
(2004) reviewed 25 reported thrombotic events in
hemophiliacs and found that a predisposing cause was
found in 15/18 (83%) spontaneously reported cases and 5
of 7 (71%) clinical trial patients. Eleven of the 25 patients
had received concomitant therapy with activated
prothrombin complexes or antifibrinolytic agents. This is
consistent with our experience of a young patient
developing deep vein thrombosis following sequential use
or rFVIIa and prothrombin complexes (Ng et al 2004).
A recent review of adverse events reported to the FDA
suggests that most thromboembolic events are associated
with use of rFVIIa for “off-label” indications, with serious
morbidity and mortality (O’Connell et al 2006). Pre-existing
risk factors for thromboembolic events were strongly
associated with these events. In the most compelling evidence
of possible thromboembolic risk associated with rFVIIa,
serious thromboembolic event rates of 7% (mainly myocardial
and cerebral infarction) were reported in a randomized
placebo controlled study of rFVIIa for intracerebral
hemorrhage involving 399 patients (Mayer et al 2005). This
was in comparison to 2% in patients receiving the placebo
(p = 0.12). While the characteristics of patients with respect
to underlying medical conditions were not well defined, it is
likely that the subjects (median age in study groups between
64–68 years) in this study represent an “at risk population”.
Furthermore, the incidence of these events, expressed as a
percentage of the number of patients in each study group,
was highest (10%) in those receiving 160 µg/kg, the highest
dosage used. Using data from the FDA pharmacovigilance
program, thrombotic events after rFVIIa have also been
compared against FEIBA and appear to be more frequent for
rFVIIa (incidence rate ratio, 2.98; CI 1.71–5.52) (Aledort
2004).
As larger doses and more intensified regimens are being
studied for hemophiliacs, thrombotic risks with rFVIIa need
to be better characterized. It remains to be defined what a
“safe” dosing regimen will be, especially for older patients.Vascular Health and Risk Management 2006:2(4) 438
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Antigenicity
As with the use of clotting factor replacement in the
hemophilias, there have been concerns about the possibility
of inhibitor development against rVIIa in patients receiving
this therapy. This has so far proved unfounded among the
hemophiliacs. Nicolaisen followed up a series of 267 patients
given rFVIIa, (including 238 hemophiliacs) for over 9 years with
no evidence of inhibitor development (Nicolaisen et al 1998). In
contrast, antibodies to rFVIIa have been isolated among 6
patients with hemophilia A and B with high responding inhibitors
(Astermark et al 2002). Because of multiple exposure to other
bypassing and blood products, causality with use of rFVIIa
could not be assigned. Other studies and ongoing experience
have not unveiled significant development of inhibitors against
rFVIIa among hemophiliacs. At this juncture, the potential for
development of inhibitors against rFVIIa in hemophiliacs have
not been conclusively disproved and vigilance, as in patients
with factor VII deficiency, must continue.
Conclusion
As a bypassing agent, rFVIIa does not fully replicate the
effectiveness of pure factor replacement therapy for bleeding
episodes in hemophiliacs without inhibitors, nor allow
prophylaxis against spontaneous bleeding events. Responses,
while impressive, are less than universal and remain
unpredictable. It has, nonetheless, advanced the treatment of
this unfortunate group of patients and allowed them to benefit
from many elective and emergency surgical procedures.
rFVIIa’s success with hemophiliacs has been extrapolated to
an increasing number of “off-label” indications. Exciting work
is currently taking shape for these new indications with more
randomized well-controlled trials being conducted. Rather
than diverting attention away from hemophiliacs, these
studies have produced valuable data with respect to many
unresolved issues in hemophiliacs, such as improved dosing
strategies and safety data. rFVIIa, in combination with normal
clotting factor replacement, may even play a role in better
controlling difficult bleeding situations in hemophiliacs
without inhibitors.
For the present, outstanding issues that can be surmised
from this review are as follows: (Table 2)
z Optimal dosing strategies remain inadequately defined.
While the trend is towards higher bolus and CI doses, it is
likely that the chosen optimal dose will need to be tailored
to the individual patient and clinical situation, for this
strategy to be cost effective. There will be a limit on the
quantum of rFVIIa that can be given, after which no further
significant benefit can be derived and safety and cost
effectiveness becomes compromised.
z Objective and easily obtainable measures of adequate
response, which may be based on thrombin generation,
thromboelastography, plasma concentrations, or
combinations of these and other surrogate markers, need
to be further developed for this issue of optimal dosing to
be resolved.
z For a treatment that is extremely expensive, cost-
effectiveness remains of utmost importance and must form
part of the equation in any true “optimal dosing”. A greater
role for FEIBA in this aspect cannot be ignored.
z There is a place for both bolus dosing and continuous
infusion strategies but CI protocols need to be better
defined. Efforts should also continue to develop more
user-friendly and effective early home treatment strategies,
which can provide better outcomes.
z While remarkably safe so far, safety concerns will likely
feature more prominently once this agent is extended
to a wider spectrum of patients. Current studies that
dispel concerns about thromboembolic risks with
incremental doses were confined to young subjects. As
this dosing strategy becomes more accepted, it is likely
that older patients with significant thromboembolic risk
factors will be included and challenge this notion of
safety.
Finally, with these shortcomings, we should continue our
search for the ideal bypassing agent – one that is universally
effective, cheap, easily administered, has a long half-life,
suitable for prophylaxis strategies, uniform in dose
requirement and, ultimately, safe.
References
Abshire T, Kenet G. 2004. Recombinant factor VIIa: review of efficacy,
dosing regimens and safety in patients with congenital and acquired
factor VIII or IX inhibitors. J Thromb Haemost, 2:899–909.
Aledort LM. 2004. Comparative thrombotic event incidence after
infusion of recombinant factorVIIa versus factor VIII inhibitor
bypass activity. J Thromb Haemost, 2:1700–8.
Allen G, Aledort L. 2006. Therapeutic decision-making in inhibitor
patients. Am J Hematol, 81:71–2.
Table 2  Unresolved issues with recombinant activated factor
VII use in hemophiliacs
z Optimal dosing strategies
z Modalities for measuring and monitoring response
z Cost-effectiveness
z The place for continuous infusion
z Thrombotic risksVascular Health and Risk Management 2006:2(4) 439
RFVIIa in hemophiliac with inhibitors
Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human
coagulation factor VII therapy for intracranial hemorrhage in
patients with hemophilia A or B with inhibitors. Results of the
novoseven emergency-use program. Haemostasis, 1998.28:93–
8.
Arkin S, Blei F, Fetten J, et al. 2000. Human coagulation factor
FVIIa (recombinant) in the management of limb-threatening
bleeds unresponsive to alternative therapies: results from the
NovoSeven emergency-use programme in patients with severe
haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis,
11:255–9.
Astermark J, Ekman M, Berntorp E. 2002. Antibodies to factor VIIa in
patients with haemophilia and high-responding inhibitors. Br J
Haematol, 119:342–7.
Bech RM. 1996. Recombinant factor VIIa in joint and muscle bleeding
episodes. Haemostasis, 26Suppl 1:135–8.
Berntorp E, Donfield S, Waters J, et al. 2005. The FEIBA(R)
NovoSeven(R) Comparative Study (FENOC)— A Randomized
Evaluation of By-Passing Agents in Hemophilia Complicated by
Inhibitors. ASH Annual Meeting Abstracts, 106:324.
Blomback B, Carlsson K, Fatah K, et al. 1994. Fibrin in human plasma:
gel architectures governed by rate and nature of fibrinogen
activation. Thromb Res, 75:521–38.
Cooper HA, Jones CP, Campion E, et al. 2001. Rationale for the use
of high dose rFVIIa in a high-titre inhibitor patient with
haemophilia B during major orthopaedic procedures.
Haemophilia, 7:517–22.
Ehrenforth S, Kreuz W, Scharrer I, et al. 1992. Incidence of development
of factor VIII and factor IX inhibitors in haemophiliacs. Lancet,
339:594–8.
Ehrlich HJ, Henzl MJ, Gomperts ED. 2002. Safety of factor VIII inhibitor
bypass activity (FEIBA): 10-year compilation of thrombotic
adverse events. Haemophilia, 8:83–90.
Hedner U. 1990. Factor VIIa in the treatment of haemophilia. Blood
Coagul Fibrinolysis, 1:307–17.
Hedner U. 1996. Dosing and monitoring NovoSeven treatment.
Haemostasis, 26(Suppl 1):102–8.
Hedner U. 2006. Mechanism of action of recombinant activated factor
VII: an update. Semin Hematol, 43(Suppl 1):S105–7.
Hedner U, Glazer S, Pingel K, et al. 1988. Successful use of
recombinant factor VIIa in patient with severe haemophilia A
during synovectomy. Lancet, 2:1193.
Hedner U, Kisiel W. 1983. Use of human factor VIIa in the treatment
of two hemophilia A patients with high-titer inhibitors. J Clin
Invest, 71:1836–41.
Hilgartner M, Aledort L, Andes A, et al. 1990. Efficacy and safety of
vapor-heated anti-inhibitor coagulant complex in hemophilia
patients. FEIBA Study Group. Transfusion, 30:626–30.
Hvid I, Rodriguez-Merchan EC. 2002. Orthopaedic surgery in haemophilic
patients with inhibitors: an overview. Haemophilia, 8:288–91.
Ingerslev J, Freidman D, Gastineau D, et al. 1996. Major surgery in
haemophilic patients with inhibitors using recombinant factor VIIa.
Haemostasis, 26Suppl 1:118–23
Ingerslev J, Thykjaer H, Kudsk Jensen O, et al. 1998. Home treatment
with recombinant activated factor VII: results from one centre.
Blood Coagul Fibrinolysis, 9Suppl 1:S107–10.
Kavakli K, Makris M, Zulfikar B, et al. 2006. NovoSeven trial
(F7HAEM-1510) investigators. Home treatment of
haemarthroses using a single dose regimen of recombinant
activated factor VII in patients with haemophilia and inhibitors.
A multi-centre, randomised, double-blind, cross-over trial.
Thromb Haemost, 95:600–5.
Kenet G, Lubetsky A, Gitel S, et al. 2000. Treatment of bleeding
episodes in patients with hemophilia and an inhibitor: comparison
of two treatment protocols with recombinant activated factor VII.
Blood Coagul Fibrinolysis, 11(Suppl 1):S35–8.
Kenet G, Lubetsky A, Luboshitz J, et al. 2003. A new approach to
treatment of bleeding episodes in young hemophilia patients: a
single bolus megadose of recombinant activated factor VII
(NovoSeven). J Thromb Haemost, 1:450–5.
Key NS, Aledort LM, Beardsley D, et al. 1998. Home treatment of
mild to moderate bleeding episodes using recombinant factor VIIa
(Novoseven) in haemophiliacs with inhibitors. Thromb Haemost,
80:912–8.
Kohler M. 1999. Thrombogenicity of prothrombin complex
concentrates. Thromb Res, 95(4 Suppl 1):S13–7.
Kreuz W, Ettingshausen CE, Zyschka A, et al. 2002. Inhibitor
development in previously untreated patients with hemophilia A:
a prospective long-term follow-up comparing plasma-derived and
recombinant products. Semin Thromb Hemost, 28:285–90.
Laurian Y, Goudemand J, Negrier C, et al. 1998. Use of recombinant
activated factor VII as first line therapy for bleeding episodes in
haemophiliacs with factor VIII or IX inhibitors. Blood Coagul
Fibrinolysis, 9:155–156.
Levi M, Peters M, Buller HR. 2005. Efficacy and safety of recombinant
factor VIIa for treatment of severe bleeding: a systematic review.
Crit Care Med, 33:883–90.
Lindley CM, Sawyer WT, Macik BG, et al. 1994. Pharmacokinetics
and pharmacodynamics of recombinant factor VIIa. Clin
Pharmacol Ther, 55:638–48.
Ludlam CA. 2002. The evidence behind inhibitor treatment with
recombinant factor VIIa. Pathophysiol Haemost Thromb, 32Suppl
1:13–8.
Ludlam CA, Smith MP, Morfini M, et al. 2003. A prospective study of
recombinant activated factor VII administered by continuous
infusion to inhibitor patients undergoing elective major orthopaedic
surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol,
120:808–13.
Lusher JM. 1998. Early treatment with recombinant factor VIIa
results in greater efficacy with less product. Eur J Haematol
Suppl, 63:7–10.
Lusher JM. 2000. Acute hemarthroses: the benefits of early versus late
treatment with recombinant activated factor VII. Blood Coagul
Fibrinolysis, 11(Suppl 1):S45–9.
Lusher JM. 2002. First and second generation recombinant factor
VIII concentrates in previously untreated patients: recovery, safety,
efficacy, and inhibitor development. Semin Thromb Hemost,
28:273–6.
Lusher JM, Roberts HR, Davignon G, et al. 1998. A randomized,
double-blind comparison of two dosage levels of recombinant
factor VIIa in the treatment of joint, muscle and mucocutaneous
haemorrhages in persons with haemophilia A and B, with and
without inhibitors. rFVIIa Study Group. Haemophilia, 4:790–8.
Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, et al. 1998.
Continuous infusion of recombinant factor VIIa in patients with
haemophilia and inhibitors. Experience in The Netherlands and
Belgium. Neth J Med, 53:249–55.
Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al.
2002. Recombinant Factor VIIa Data Collection Group.
Efficacy of recombinant factor VIIa administered by
continuous infusion to haemophilia patients with inhibitors.
Haemophilia, 8:649–56.
Mayer SA, Brun NC, Begtrup K, et al. 2005. Recombinant Activated
Factor VII Intracerebral Hemorrhage Trial Investigators.
Recombinant activated factor VII for acute intracerebral
hemorrhage. N Engl J Med, 352:777–85.
Montoro JB, Altisent C, Pico M, et al. 1998. Recombinant factor VIIa
in continuous infusion during central line insertion in a child with
factor VIII high-titre inhibitor. Haemophilia, 4:762–5.
Munro FL, Jones HW. 1943. The detrimental effect of frequent
transfusions in the treatment of a patient with hemophilia. Am J M
Sc, 206:107.Vascular Health and Risk Management 2006:2(4) 440
Ng and Lee
Negrier C, Goudemand J, Sultan Y, et al. 1997. Multicenter retrospective
study on the utilization of FEIBA in France in patients with factor
VIII and factor IX inhibitors. French FEIBA Study Group. Factor
Eight Bypassing Activity. Thromb Haemost, 77:1113–9.
Ng HJ, Loh SM, Tan DC, et al. 2004. Thrombosis associated with the
use of recombinant activated factor VII:profiling two events.
Thromb Haemost, 92:1448–9.
Nicolaisen EM. 1998. Antigenicity of activated recombinant factor
VII followed through nine years of clinical experience. Blood
Coagul Fibrinolysis, 9(Suppl 1):S119–23.
O’Connell KA, Wood JJ, Wise RP, et al. 2006. Thromboembolic adverse
events after use of recombinant human coagulation factor VIIa.
JAMA, 295:293–8.
Parameswaran R, Shapiro AD, Gill JC, et al. 2005. HTRS Registry
Investigators. Dose effect and efficacy of rFVIIa in the treatment
of haemophilia patients with inhibitors: analysis from the
Hemophilia and Thrombosis Research Society Registry.
Haemophilia, 11:100–6.
Rice KM, Savidge GF. 1996. NovoSeven (recombinant factor VIIa)
in central nervous systems bleeds. Haemostasis, 26(Suppl
1):131–4.
Rodriguez-Merchan EC, Rocino A, Ewenstein B, et al. Consensus
perspectives on surgery in haemophilia patients with inhibitors:
summary statement. Haemophilia, 2004.10 Suppl 2:50–2.
Santagostino E, Gringeri A, Mannucci PM. 1999. Home treatment with
recombinant activated factor VII in patients with factor VIII inhibitors:
the advantages of early intervention. Br J Haematol, 104:22–6.
Santagostino E, Mancuso ME, Rocino A, et al. 2006. A prospective
randomized trial of high and standard dosages of recombinant
factor VIIa for treatment of hemarthroses in hemophiliacs with
inhibitors. J Thromb Haemost, 4:367–71.
Scharrer I. 1999. Recombinant factor VIIa for patients with inhibitors
to factor VIII or IX or factor VII deficiency. Haemophilia, 5:253–
9.
Scharrer I, Bray GL, Neutzling O. 1999. Incidence of inhibitors in
haemophilia A patients a review of recent studies of recombinant
and plasma-derived factor VIII concentrates. Haemophilia, 5:145–54.
Schulman S, Bech Jensen M, et al. 1996. Feasibility of using
recombinant factor VIIa in continuous infusion. Thromb Haemost,
75:432–6.
Shapiro AD, Gilchrist GS, Hoots WK, et al. 1998. Prospective, randomised
trial of two doses of rFVIIa (NovoSeven) in haemophilia patients
with inhibitors undergoing surgery. Thromb Haemost, 80:773–8.
Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. 1981. The
effect of activated prothrombin-complex concentrate (FEIBA)
on joint and muscle bleeding in patients with hemophilia A and
antibodies to factor VIII. A double-blind clinical trial. N Engl J
Med, 305:717–21.
Smith MP, Ludlam CA, Collins PW, et al. 2001. Elective surgery on
factor VIII inhibitor patients using continuous infusion of
recombinant activated factor VII: plasma factor VII activity of 10
IU/ml is associated with an increased incidence of bleeding. Thromb
Haemost, 86:949–53.
Villar A, Aronis S, Morfini M, et al. 2004. Pharmacokinetics of
activated recombinant coagulation factor VII (NovoSeven) in
children vs. adults with haemophilia A. Haemophilia, 10:352–9.
von Depka M. 2005. Managing acute bleeds in the patient with
haemophilia and inhibitors: options, efficacy and safety.
Haemophilia, 11(Suppl 1):18–23.
Warrier I, Lusher JM. 1998. Development of anaphylactic shock in
haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis,
9(Suppl 1):S125–8.